Loading...

Resources

Is Your Provider Agile?

Is Your Provider Agile?

There are a host of technical terms that get thrown around when discussing software implementations and outsourcing solutions. Understandably, these concepts are often misused or confused, which can improperly influence our decision-making and ultimately our allocation of resources. In this article, we will explore some key terms and how we can properly apply them to business planning and vendor management as we move into the modern digital age.

Read More
Proposed Rule on Multiple BPs

Proposed Rule on Multiple BPs

The proposed changes to BP reporting in the Medicaid Proposed Rule represent real progress toward addressing manufacturers’ gross-to-net and operational concerns around value-based pricing arrangements. Sounds great, right… so what’s the catch?

Read More
Accumulator Programs Impact on BP

Accumulator Programs Impact on BP

The Proposed Rule includes a revision that can result in manufacturer-sponsored patient assistance programs being included in Best Price. In order to estimate the financial impact of this proposed revision, manufacturers will first need to determine how to incorporate manufacturer-sponsored patient assistance program transactions in Best Price.

Read More
COVID Part 1: How Can the Macroeconomic Effects of COVID-19 Impact Medicaid Liabilities and Accrual Forecasting?

COVID Part 1: How Can the Macroeconomic Effects of COVID-19 Impact Medicaid Liabilities and Accrual Forecasting?

Undoubtedly, COVID-19 will leave an unprecedented impact on our economy for months, if not years, to come. While the life sciences industry is on the front lines of battle against COVID-19 working on vaccinations and treatments to combat the virus, manufacturers must understand and prepare for the potentially significant financial implications to their Government Programs.

Read More
COVID Part 2: How Can the Effects of COVID-19 Create Shifts in Market Segmentation & 340B Covered Entities?

COVID Part 2: How Can the Effects of COVID-19 Create Shifts in Market Segmentation & 340B Covered Entities?

While the life sciences industry is on the front lines of battle against COVID-19 working on vaccinations and treatments to combat the virus, manufacturers must understand and prepare for how the shifts in demand and patient populations will impact their Government Program liabilities and Gross-to-Net.

Read More
COVID-19 Part 3: COVID-19 Relief Efforts and Government Pricing Considerations

COVID-19 Part 3: COVID-19 Relief Efforts and Government Pricing Considerations

The COVID-19 pandemic has created a pressing need not only for medicines that help treat known COVID-19 symptoms and vaccines against the virus, but also significant demand for the treatment of prevalent health issues potentially related to COVID-19.

Read More
COVID-19 Part 4: Redefining Product Launch Strategy After COVID-19

COVID-19 Part 4: Redefining Product Launch Strategy After COVID-19

The COVID-19 pandemic is causing tremendous shifts in both supply and demand for the Life Sciences industry. Manufacturers are gearing up for these changes, while trying to meet the needs of a suddenly changed market. For manufacturers imminently planning product launches in these turbulent times, adjusting strategies for these changes will be critically important.

Read More
COVID-19 Part 4: Redefining Product Launch Strategy After COVID-19

Inflation-Based Rebates for Medicare Part B and Part D Covered Drugs

Of note, there are similar provisions in both the House and the Senate committee bills. Relevant to pharmaceutical manufacturers, both bills introduce an inflation-based rebate using the Consumer Price Index- Urban (“CPI-U”) for both Medicare Part B and Part D covered drugs. This paper provides a comparison of these rebate provisions, along with mathematical examples illustrating those differences. This analysis is not intended to offer legal or regulatory advice and is based on our general experience in the industry. Our interpretations may differ from the views and intentions of the lawmakers that authored the relevant legislation.

Read More
CIO Review

CIO Review

10 Most Promising Healthcare Tech Startups - 2019

Read More
Pharma Tech Outlook 2019

Pharma Tech Outlook 2019

Top 10 Enterprise Software Solution Providers 2019

Read More